#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Endologix appoints Thomas C. Wilder to its board of directors

Share on Twitter Share on LinkedIn
Staff writer | Irvine, Ca., USA | May 21, 2010
EndologixMay 21, 2010, Irvine, Ca., USA - Endologix, Inc., a developer of minimally invasive treatments for aortic disorders, announced that Thomas C. Wilder has joined the Endologix board of directors.
Mr. Wilder currently serves as President and CEO of Sequent Medical, a private company focused on developing innovative devices for the treatment of neurovascular disease. Prior to joining Sequent Medical, Mr. Wilder was President and CEO of Photothera, a private company developing transcranial laser therapy for the treatment of acute ischemic stroke.

Prior to Photothera, Mr. Wilder was President and CEO of Micro Therapeutics. Prior to Micro Therapeutics, Mr. Wilder held several positions during an eleven-year tenure at Medtronic, including Vice President & General Manager, Endovascular Stent Grafts; Vice President, Finance, IT and Business Development at Medtronic Vascular; and roles of increasing responsibility as a five-year expatriate in both Europe and Asia.

Mr. Wilder holds a BA in Economics, with distinction, from Stanford University and a Master of Management, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University.

Mr. Wilder replaces Paul McCormick, whose term on the Board expired at the Annual Meeting.